Before the approval of andexanet alfa, no specific reversal agents were available for factor Xa inhibitors instead, inactivated prothrombin complex concentrates (PCCs) were used off-label as first-line agents for factor Xa inhibitor reversal. 2 Like all anticoagulants, these medications carry a risk of bleeding. The purpose of this article is to describe the updated literature for andexanet alfa in the setting of factor Xa inhibitor reversal.įactor Xa inhibitors (rivaroxaban, apixaban, edoxaban, and betrixaban) are commonly used for anticoagulation. Since the publication of this review, additional studies and recommendations for andexanet alfa use have been published. In August 2018, the UIC Drug Information Group reviewed the literature related to the use of andexanet alfa for the reversal of factor Xa inhibitors.
0 Comments
Leave a Reply. |